Trial Profile

Evaluation of the Clinical Benefit of ToFAcitinib Treatment in Patients With Moderate to Severe Ulcerative Colitis Under Real-life Conditions of Use: TOFAst Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms TOFAST
Sponsors Pfizer

Most Recent Events

01 Oct 2024 Protocol has been amended to change in study time frame for its primary endpoint.
02 Feb 2023 Planned End Date changed from 30 Nov 2024 to 30 Jun 2026.
02 Feb 2023 Planned primary completion date changed from 30 Nov 2024 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com